CALGB 8811 — A Five-Drug Remission Induction Regimen with Intensive Consolidation for Adults with Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811

Phase II · 1995 · Acute Lymphoblastic Leukemia

Design

Multicenter phase II trial of an intensive, pediatric-inspired multi-agent chemotherapy program (the Larson regimen) with five-drug induction and intensive consolidation for adults with untreated ALL.

Population

197 eligible adults (ages 16-80; median 32) with newly diagnosed, previously untreated acute lymphoblastic leukemia.

Primary Endpoint

Complete remission rate

Key Result

167 of 197 patients (85%) achieved complete remission, with CR rates of 94% in patients =60 years (P<0.001).

Guideline Impact

Backbone regimen for adult ALL induction/consolidation